1-Preminger GM. Stones in the urinary track. In: cutler RE (ed.) the merck manual medical information home edition (3^rd ed.).  whitehouse station, new jersey. 2007.

2.Barnela SR, Soni SS, Saboo SS, Bhansali AS.Medical management of renal stone.   Indian J Endocrinol Metab. 2012, Mar; 16(2):236-9.

3.Sakhaee K, Maalouf NM, Sinnott B.Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab, 2012 Jun;97(6):1847-60.

4.Safarinejad MR. The epidemiology of adult chronic kidney disease in a population-based study in Iran: prevalence and associated risk factors. J NepHrol.2009 Jan-Feb; 22(1):99-108.

5.Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology, 2004 Feb 15; 195(2-3):221-30.

6.Cosens DJ, Manning A. Abnormal electroretinogram from a Drosophila  mutant.  1969 Oct 18;224(5216):285-7.

7.Huang HS, Chen J, Chen CF, Ma MC. Vitamin E attenuates crystal formation in rat kidneys: Roles of renal tubular cell death and crystallization inhibitors. Kidney Int, 2006; 70(4):699-710.

8.Renkema KY, Lee K, Topala CN, Goossens M, Houillier P, Bindels RJ, et al. TRPV5 gene polymorpHisms in renal hypercalciuria. NepHrol Dial Transplant.

 2009; 24(6):1919-24.

9.Wang L, Holmes RP, Peng JB. Modeling the structural and dynamical changes of the epithelial calcium channel TRPV5 caused by the A563T variation based on the structure of  TRPV6. J Biomol  Struct  Dyn. 2018; 3:1-24.

10.Wikipcdia.org.{Homepage on the Internet}.Transient receptor potential cation channel subfamily V member 5. {Updated on 29 June 20018, at 16:10(UTC)}.Available from:https://en.wikipedia.org/wiki/TRPV5.

11.Wang L, Holmes R, Peng j, M0lecular Modeling of the Structural and Dynamical Changes in Calcium Channel TRPV5 Induced by the African-Specific A563T Variation.Biochemistry.2016;55(8):1254-1264.

12.Wang L,Holmes R, Peng j.The L530R variation associated with recurrent kidney stones impairs the structure and function of TRPV5.Biochem and biophy res com.2017;492(3).362-367.

13.Einollahi B, Naghii MR, Sepandi M. Association of nonalcoholic fatty liver disease (NAFLD) with urolithiasis. Endocr Regul, 2013 Jan; 47(1):27-32.

14.Balaji KC, Menon M. Mechanism of stone formation. Urol Clin North Am. 1997 Feb; 24(1):1-11.

15.Wu Y, Miyamoto T, Li K, Nakagomi H, Sawada N, Kira S, et al. Decreased expression of the epithelial Ca2+ channel TRPV5 and TRPV6 in human renal cell carcinoma associated with vitamin D receptor. J Urol. 2011;186(6):2419-25.

16.Lingyun Wang, Ross P.Holmes,b and Ji-Bin peng. The L530R variation associated with  recurrent   kidney stones impairs the structure and function of TRPV5. Biochem      Biophys Res Commun.  2017 Oct 21; 492(3): 362-367.

17.Tao Na,Wei Zhang, Yi Jiang, Youyou Liang, He-Ping Ma, David G. Warnock, et al. The A563T   variation   of  The  renal  epithelial  calcium channel TRPV5 among Africa Americans enhances  calcium influx. Am J Physio Renal Physiol.2009May; 296(5): F1042-F1051.